Skip to main content

Upadacitinib Dosage

Medically reviewed by Drugs.com. Last updated on Sep 15, 2023.

Applies to the following strengths: 45 mg; 15 mg; 30 mg; 1 mg/mL

Usual Adult Dose for Rheumatoid Arthritis

15 mg orally once a day

Comments:


Use: Treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers.

Usual Adult Dose for Psoriatic Arthritis

15 mg orally once daily

Comments:


Use: Adults with active psoriatic arthritis with inadequate response or intolerance to TNF blockers

Usual Adult Dose for Atopic Dermatitis

Initiation dose: 15 mg orally once daily
Maximum dose: 30 mg orally once daily (if no response with initial dose)
Duration of therapy: Discontinue if no response is achieved with 30 mg/day dose

Comments:


Use: Adults with refractory, moderate to severe atopic dermatitis that has not been adequately controlled with other systemic drug products, including biologics, or when other therapies are inadvisable

Usual Adult Dose for Ulcerative Colitis - Active

Induction dosage: 45 mg orally once a day for 8 weeks. This dosage can be continued for 8 additional weeks in patients with no adequate response.
Maintenance dosage: 15 or 30 mg once a day
Maximum dosage: 30 mg once a day can be considered for patients with refractory, severe, or extensive disease.

Comments:


Use: Treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers.

Usual Adult Dose for Ulcerative Colitis - Maintenance

Induction dosage: 45 mg orally once a day for 8 weeks. This dosage can be continued for 8 additional weeks in patients with no adequate response.
Maintenance dosage: 15 or 30 mg once a day
Maximum dosage: 30 mg once a day can be considered for patients with refractory, severe, or extensive disease.

Comments:


Use: Treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers.

Usual Adult Dose for Crohn's Disease - Acute

Induction dosage: 45 mg orally once a day for 12 weeks
Recommended maintenance dosage: 15 mg once a day
Maximum dosage: 30 mg once a day can be considered for patients with refractory, severe, or extensive disease.

Comments:


Use: Treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response or intolerance to one or more TNF blockers.

Usual Adult Dose for Crohn's Disease - Maintenance

Induction dosage: 45 mg orally once a day for 12 weeks
Recommended maintenance dosage: 15 mg once a day
Maximum dosage: 30 mg once a day can be considered for patients with refractory, severe, or extensive disease.

Comments:


Use: Treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response or intolerance to one or more TNF blockers.

Usual Adult Dose for Ankylosing Spondylitis

Recommended dosage: 15 mg orally once daily

Comments:


Use: Adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers. with inadequate response or intolerance to TNF blockers

Usual Adult Dose for Axial Spondyloarthritis

Recommended dosage: 15 mg orally once daily

Comments:


Use: Adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation who have had an inadequate response or intolerance to TNF blocker therapy.

Usual Geriatric Dose for Atopic Dermatitis

Adults 65 years of age and older: 15 mg orally once daily

Comments:


Use: Adults 65 years and older with refractory, moderate to severe atopic dermatitis that has not been adequately controlled with other systemic drug products, including biologics, or when other therapies are inadvisable

Usual Pediatric Dose for Atopic Dermatitis

Patients 12 years of age and older weighing at least 40 kg:
Initiation dose: 15 mg orally once daily
Maintenance dose: 30 mg orally once daily (if no response with initial dose)
Maximum dose: 30 mg orally once daily
Duration of therapy: Discontinue if no response is achieved with 30 mg dose

Comments:


Use: Pediatric patients older than 12 years old and weighing at least 40 kg with refractory, moderate to severe atopic dermatitis that has not been adequately controlled with other systemic drug products, including biologics, or when other therapies are inadvisable

Renal Dose Adjustments

Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis:
No adjustment recommended.

Atopic Dermatitis:


Ulcerative Colitis:

Crohn's Disease:

Liver Dose Adjustments

Rheumatoid Arthritis, Psoriatic Arthritis, Atopic Dermatitis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis:
Mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment: No adjustment recommended.
Severe (Child-Pugh C) hepatic impairment: Not recommended.

Ulcerative Colitis:
Mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment:

Severe (Child-Pugh C) hepatic impairment: Not recommended.

Crohn's Disease:
Mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment:
Severe (Child-Pugh C) hepatic impairment: Not recommended.

Dose Adjustments

PATIENTS RECEIVING STRONG CYP450 3A4 inhibitors:
Rheumatoid Arthritis, Psoriatic Arthritis, Atopic Dermatitis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis:


Ulcerative Colitis:

Crohn's Disease:

INFECTIONS:

RECOMMENDED DOSE INTERRUPTIONS FOR LABORATORY ABNORMALITIES:
cells/mm3; restart when ANC is above 1000 cells/mm3.
cells/mm3; restart when ANC is above 500 cells/mm3.

Precautions

US FDA requires a medication guide to assure safe use. For additional information: www.fda.gov/drugs/drug-safety-and-availability/medication-guides

US BOXED WARNINGS:
SERIOUS INFECTIONS:

MORTALITY
MALIGNANCIES:
THROMBOSIS:

CONTRAINDICATIONS:

Safety and efficacy have not been established in patients younger than 18 years for rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, Crohn's disease, ankylosing spondylitis, and non-radiographic axial spondyloarthritis.
Safety and efficacy have not been established in patients younger than 12 years for atopic dermatitis.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Prior to treatment initiation:


Administration advice:

Storage requirements:

General

Monitoring:

Patient advice:

Frequently asked questions

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.